Loading
Life sciences · Journal article
Cureus · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
IntroductionIn February 2025, a single infant with carbamoyl phosphate synthetase 1 deficiency received a customized base-editing therapy, and individualized gene editing has since been discussed as an emerging category of care.No one has yet counted whether this category exists in the registered study record. MethodsWe conducted a cross-sectional census of interventional studies of human gene-editing agents registered on ClinicalTrials.gov.Records were retrieved through the ClinicalTrials.govapplication programming interface, version 2, with a verbatim, intervention-scoped query and a fixed census date of 17 September 2026.Eligibility was verified from each record's own fields, and every exclusion is supported by the field value that justifies it.Two independent screening passes classified each eligible record as single-participant or n-of-1, multi-variant umbrella or platform-designated, or conventional cohort.Agreement was quantified with Cohen's kappa and a 95% confidence interval (CI).Records in the individualized and platform classes were re-verified against their complete registry entries and version histories.We also searched public US Food and Drug Administration (FDA) records for the regulatory route of each census record.Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. ResultsOf 212 retrieved records, 64 were excluded, and 148 were eligible.Four eligible records were singleparticipant or n-of-1 designs, and three were multi-variant umbrella or platform-designated designs, giving a census of seven studies.Of the remainder, 140 were conventional cohorts, and one was an editing arm inside a non-editing platform trial.Version histories confirmed the four single-participant designs; one of them reached an enrolment of one through a revision made before enrolment began.The same histories showed that three other records had an enrolment of one or two only because of termination or underenrolment.Only two of the 148 eligible records describe a construct designed for the individual participant.No publicly verifiable platform technology designation was located for any census record, and the census query returned no expanded-access record.Of 23 studies completed more than 12 months before the census, five had posted results (21.7%, Wilson 95% CI: 9.7%-41.9%);because this interval is wide, the figure is reported as context only.Agreement on design class was moderate (kappa, 0.540; 95% CI, 0.264-0.815). ConclusionsNineteen months after the first individualized CRISPR treatment, the registry contains seven individualized or platform-designated gene-editing studies, and only two records describe an individualized construct.The regulatory pathway used by the index case was not retrievable from the registry, and no regulatory route could be verified from public records; this is an absence of public evidence, not evidence that no route existed.These counts describe the ClinicalTrials.govrecord, not the prevalence of individualized gene editing, and the design-class counts are provisional given moderate agreement.